CAS 1007573-18-3

N-(2,3-Dihydro-1H-inden-2-yl)-3,5-difluoro-3′-(1H-1,2,4-triazol-5-yl)[1,1′-biphenyl]-4-methanamine

CAS: 1007573-18-3

Fórmula: C₂₄H₂₀F₂N₄

Pureza: 98.55%

Cor e Forma: Solid

Peso molecular: 402.4392

Ref: IN-DA0002TH

GSK1521498 free base

CAS: 1007573-18-3

GSK1521498 free base

Pureza: ≥98%

Peso molecular: 402.44g/mol

Ref: 54-BUP21441

GSK-1521498

CAS: 1007573-18-3

GSK-1521498 is a new investigational drug that has been shown to reduce inflammation and oxidative stress in preclinical models. It targets multiple pathways, including the renin-angiotensin system, endoplasmic reticulum stress, and insulin signaling. In preclinical models, GSK-1521498 has been shown to reduce the prevalence of cancer and metabolic disorders such as type 2 diabetes. More research is needed to determine whether GSK-1521498 would be effective in humans.

Fórmula: C₂₄H₂₀F₂N₄

Pureza: Min. 95%

Peso molecular: 402.4 g/mol

Ref: 3D-HQB57318

GSK1521498 free base

CAS: 1007573-18-3

GSK1521498 free base is an effective and selective μ-opioid receptor antagonist with potential applications in obesity, alcoholism, and drug addiction.

Fórmula: C₂₄H₂₀F₂N₄

Pureza: 99.85%

Cor e Forma: Solid

Peso molecular: 402.44

Ref: TM-T11478L